Conferences - Results from #80

ASCO GU 2021: Molecular Determinants Associated with Long-Term Response to Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) February 18, 2021

ASCO GU 2021: The Role of PARP Inhibitors in Prostate Cancer: Is It a Sea Change or Just Another Incremental Change? February 18, 2021

ASCO GU 2021: Role of Definitive Local Therapy After Complete Clinical Response to Neoadjuvant Chemotherapy February 18, 2021

ASCO GU 2021: The Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC): Updated Follow-up of a Phase I/II Study February 18, 2021

ASCO GU 2021: Optimal Radiologic Assessment After Systemic Therapy for Muscle-Invasive Bladder Cancer February 18, 2021

ASCO GU 2021: Phase 3 Trial of Lenvatinib plus Pembrolizumab or Everolimus Versus Sunitinib Monotherapy as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (CLEAR Study) February 18, 2021

ASCO GU 2021: Patient Perspective on Newly Diagnosed Muscle-Invasive Bladder Cancer: What Do I Hope the Doctor Will Address? February 18, 2021

ASCO GU 2021: First Results from the Phase 3 CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma February 18, 2021

ASCO GU 2021: Impact of Equal Access Healthcare on Race Disparities in Bladder Cancer February 18, 2021

ASCO GU 2021: Phase II Clinical Study of Concurrent Durvalumab and Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Localized Urothelial Cancer of Bladder: Results for Primary Analyses and Survival. BTCRC-GU15-023 February 18, 2021

ASCO GU 2021: Phase II Study of Gemcitabine and Split-Dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy (RC) in Patients with Muscle-Invasive Bladder Cancer (MIBC) February 18, 2021

ASCO GU 2021: Uncertainties in the Timing and Sequencing of Therapies for Metastatic Disease February 18, 2021

ASCO GU 2021: A Phase II Trial Of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy For Bladder Cancer (RETAIN BLADDER): Interim Analysis February 18, 2021

ASCO GU 2021: Uncertainties in the Optimal Delivery of Trimodality Therapy February 18, 2021

ASCO GU 2021: A Multicenter Retrospective Analysis Examining The Effect Of Dipeptidyl Protease 4 Inhibitors On Progression-Free Survival In Patients With Prostate Cancer February 17, 2021

ASCO GU 2021: Concordance of BRCA1 and BRCA2, and ATM Mutations Identified in Matched Tumor Tissue and ctDNA in Men mCRPC Screened in the PROfound Study February 17, 2021

ASCO GU 2021: Patterns of Progression in Patients Treated with Nivolumab plus Ipilimumab (NIVO+IPI) Versus Sunitinib (SUN) for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214 February 17, 2021

ASCO GU 2021: Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) February 17, 2021

ASCO GU 2021: The Efficacy and Safety of Nivolumab Plus Docetaxel For Chemotherapy-Naïve mCRPC in the Final Analysis of the CheckMate 9KD Arm B Trial February 17, 2021

ASCO GU 2021: Enfortumab Vedotin in Previously Treated Urothelial Cancer - Results of EV-301 & EV-201 Cohort 2 Discussion February 17, 2021

Page 5 of 392